VIVUS, Nordmark revise contract agreement for PANCREAZE development
Category: #health  By Paroma Bhattacharya  Date: 2019-06-28
  • share
  • Twitter
  • Facebook
  • LinkedIn

VIVUS, Nordmark revise contract agreement for PANCREAZE development

California-headquartered biopharmaceutical firm VIVUS Inc. has recently announced an amendment to its contract manufacturing and supply agreement of delayed release capsules PANCREAZE® with Nordmark Arzneimittel GmbH & Co. KG.

Apparently, the revised treaty covers an initial term of 10 years followed by a renewal of additional five years. Financial terms of the agreement remained undisclosed.

Citing reliable sources, VIVUS and Nordmark will work together under the terms of the agreement to develop an advanced formulation of PANCREAZE, which is expected to enter the market by 2021, with the prime goal of extending its shelf life.

John Amos, Chief Executive Officer, VIVUS, was quoted saying that ensuring the supply of PANCREAZE to meet current and future demands of the drug at a predictable and stable price was their key strategy. He further added that with their current product formulations, there lies a bright future for PACREAZE market to create additional commercial and clinical value with the introduction of the product’s advanced formulations.

Nordmark CEO Jörn Tonne stated that their firm has managed to achieve considerable expertise in manufacturing PANCREAZE, and they look forward to extending their agreement with VIVUS. He also mentioned that they have had a successful record in developing new products to meet customer needs as well as the patients they serve.

Tonne noted that Nordmark plans to work with VIVUS in developing advanced formulations of PANCREAZE that make the drug even more convenient for patients diagnosed with exocrine pancreatic insufficiency.

For the record, PANCREAZE is a prescription drug used for treatment of patients who have difficulty digesting food normally because their pancreas, due to cystic fibrosis or other conditions, is unable to produce enough enzymes. PANCREAZE contains a mixture of digestive enzymes including amylases, proteases and lipases from pig pancreas, that helps body use up proteins, sugars and fats from food. The drug is effective and completely safe in children when taken in prescribed doses.

 

Source credit: https://www.nasdaq.com/press-release/vivus-and-nordmark-amend-contract-manufacturing-agreement-to-supply-current-and-future-demand-for-20190626-00835



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
By Paroma Bhattacharya

Mirati Therapeutics, an oncology company that engages in the development of targeted therapies, recently released its clinical trial results for MRTX849. Reportedly, MRTX849 is a KRAS G12C inhibitor and the data from P...

Best Buy to offer free next-day delivery feature on various products
Best Buy to offer free next-day delivery feature on various products
By Paroma Bhattacharya

Online retailers are always launching new and attractive deals during the holiday season, as it grosses the highest sale time for the year. Several retailer rollout out attractive offers, such as discounts or complimen...

Nature Tech Corp partners with Aldevron for gene therapy manufacturing
Nature Tech Corp partners with Aldevron for gene therapy manufacturing
By Paroma Bhattacharya

The global cell and gene therapy sector is expected to witness a thriving period of growth over the forthcoming years. In fact, owing to the favorable growth conditions across the industry, numerous biotechnology and p...